FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileRegeneRx Biopharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RGRX
RegeneRx Biopharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for RegeneRx Biopharmaceuticals, Inc. (RGRX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRGRX
RGRX
RegeneRx Biopharmaceuticals, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RGRX
  1. Home
  2. Stocks
  3. RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc.

🇺🇸RGRX•OTC

RegeneRx Biopharmaceuticals, Inc.

🇺🇸RGRX•OTC
Market cap
$449
Sentiment

Your view on RGRX

Mkt Cap
$449
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About RegeneRx Biopharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
J. J. Finkelstein
Headquarters
15245 Shady Grove Road, Rockville, MD, US
Industry
Biotechnology
Sector
Healthcare
CEO
J. J. Finkelstein
Headquarters
15245 Shady Grove Road, Rockville, MD, US
Description

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration.

The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue.

It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for RegeneRx Biopharmaceuticals, Inc. from FRC's valuation model, read against the market price. RGRX last traded at $0.0003; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for RegeneRx Biopharmaceuticals, Inc.. Starting points for RegeneRx Biopharmaceuticals, Inc.: EPS -$0.01, beta 4.73 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for RegeneRx Biopharmaceuticals, Inc.. RegeneRx Biopharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for RegeneRx Biopharmaceuticals, Inc.. Trailing twelve-month EPS for RegeneRx Biopharmaceuticals, Inc. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Analyst Ratings

Buy1 rating
  • Strong Buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2017
Avg. estimate$0.00
Low estimate$0.00
High estimate$0.00
No. of analysts0
Year-ago EPS—
Growth—

Revenue Estimate

RevenueCurrent QtrDec 2017
Avg. estimate$13500.00
Low estimate$10000.00
High estimate$17000.00
No. of analysts1
Year-ago revenue—
Growth—
Recent analyst actions1 rating and price-target change, latest Mar 14, 2016 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for RegeneRx Biopharmaceuticals, Inc.. RegeneRx Biopharmaceuticals, Inc. has reported as a listed company since 2003. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold RGRX18 companies
Compare RGRX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • CHNXFChitogenX Inc.Biotechnology$627,628
  • DRWNQuantum Medical Transport, Inc.Medical - Care Facilities$23,978
  • FFNTF4Front Ventures Corp.Drug Manufacturers - Specialty & Generic$62,300
  • FORZForza Innovations Inc.Medical - Devices$252,183
  • HMGNHemagen Diagnostics, Inc.Biotechnology$3,100
  • NBIONascent Biotech, Inc.Biotechnology$51,665

More Biotechnology companies

  • ORGSOrgenesis Inc.OTC$3M
  • ORICORIC Pharmaceuticals, Inc.NASDAQ$795M
  • ORKAOruka Therapeutics, Inc.NASDAQ$6.5B
  • ORMPOramed Pharmaceuticals Inc.NASDAQ$169M
  • ORPOFOSE Immunotherapeutics S.A.OTC$260M
  • ORYZFOryzon Genomics S.A.OTC$284M
  • OSRHWOSR Holdings, Inc.NASDAQ$8M
  • OSTXOS Therapies IncorporatedAMEX$48M
  • OTLCOncotelic Therapeutics, Inc.OTC$21M
  • OTLKOutlook Therapeutics, Inc.NASDAQ$99M
  • OVIDOvid Therapeutics Inc.NASDAQ$427M
  • OXBOFOxford BioDynamics PlcOTC$4M
Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by RegeneRx Biopharmaceuticals, Inc. executives and directors. Shares of RegeneRx Biopharmaceuticals, Inc. have traded between $0.0002 and $0.16 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for RegeneRx Biopharmaceuticals, Inc.. Coverage tracks RegeneRx Biopharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of RegeneRx Biopharmaceuticals, Inc.

RGRX Analysis
Weak
Past1
Growth1
Health5
Profit1
Value1

News

Latest Market News